Skip to main content

Medications for Macular Degeneration

Medically reviewed by Carmen Pope, BPharm. Last updated on Feb 20, 2024.

There are two types of age-related macular degeneration (AMD): dry and wet (the wet form is also called neovascular AMD). Treatment options for dry AMD include the AREDS2 supplement to slow the progression of AMD, pegcetacoplan (Syfovre) and avacincaptad pegol (Izervay). Treatment options for Wet AMD include brolucizumab-dbll (Beovu), aflibercept (Eylea and Eylea HD), ranibizumab (Lucentis), faricimab-svoa (Vabysmo), Avastin (off-label), photodynamic therapy, and laser surgery.

Contact your eye care provider promptly at any sign of visual changes.

Drugs used to treat Macular Degeneration

The following list of medications are in some way related to or used in the treatment of this condition.

Filter
Drug name Rating Reviews Activity ? Rx/OTC Pregnancy CSA Alcohol
Eylea 7.1 34 reviews for Eylea to treat Macular Degeneration
Rx C N
Generic name:
aflibercept ophthalmic
Drug class:
anti-angiogenic ophthalmic agents
For consumers:
dosage, side effects
For professionals:
Prescribing Information
Lucentis 7.5 7 reviews for Lucentis to treat Macular Degeneration
Rx C N
Generic name:
ranibizumab ophthalmic
Drug class:
anti-angiogenic ophthalmic agents
For consumers:
dosage, interactions, side effects
For professionals:
Prescribing Information
Vabysmo 7.9 9 reviews for Vabysmo to treat Macular Degeneration
Rx N
Generic name:
faricimab systemic
Drug class:
anti-angiogenic ophthalmic agents
For consumers:
dosage, side effects
For professionals:
Prescribing Information
aflibercept 6.9 37 reviews for aflibercept to treat Macular Degeneration
Rx C N
Generic name:
aflibercept ophthalmic
Brand names:
Eylea, Eylea HD
Drug class:
anti-angiogenic ophthalmic agents
For consumers:
dosage, side effects
For professionals:
AHFS DI Monograph
faricimab 7.9 9 reviews for faricimab to treat Macular Degeneration
Rx N
Generic name:
faricimab systemic
Brand name:
Vabysmo
Drug class:
anti-angiogenic ophthalmic agents
For consumers:
dosage, side effects
For professionals:
AHFS DI Monograph
pegcetacoplan Rate Add review
Rx N
Generic name:
pegcetacoplan ophthalmic
Brand name:
Syfovre
Drug class:
miscellaneous ophthalmic agents
For consumers:
dosage, interactions, side effects
For professionals:
AHFS DI Monograph
Syfovre Rate Add review
Rx N
Generic name:
pegcetacoplan ophthalmic
Drug class:
miscellaneous ophthalmic agents
For consumers:
dosage, interactions, side effects
For professionals:
Prescribing Information
avacincaptad pegol Rate Add review
Rx N
Generic name:
avacincaptad pegol ophthalmic
Brand name:
Izervay
Drug class:
anti-angiogenic ophthalmic agents
For consumers:
dosage, side effects
For professionals:
AHFS DI Monograph
Izervay Rate Add review
Rx N
Generic name:
avacincaptad pegol ophthalmic
Drug class:
anti-angiogenic ophthalmic agents
For consumers:
dosage, side effects
For professionals:
Prescribing Information
bevacizumab Off-label 10 4 reviews for bevacizumab to treat Macular Degeneration
Rx C N
Generic name:
bevacizumab systemic
Drug class:
VEGF/VEGFR inhibitors
For consumers:
dosage, interactions, side effects
For professionals:
AHFS DI Monograph
Off-label:
Yes
Beovu 7.0 3 reviews for Beovu to treat Macular Degeneration
Rx N
Generic name:
brolucizumab systemic
Drug class:
anti-angiogenic ophthalmic agents
For consumers:
dosage, side effects
For professionals:
Prescribing Information
ranibizumab 7.7 8 reviews for ranibizumab to treat Macular Degeneration
Rx C N
Generic name:
ranibizumab ophthalmic
Brand names:
Lucentis, Byooviz, Cimerli, Susvimo
Drug class:
anti-angiogenic ophthalmic agents
For consumers:
dosage, interactions, side effects
For professionals:
AHFS DI Monograph
Visudyne Rate Add review
Rx C N X
Generic name:
verteporfin systemic
Drug class:
miscellaneous antineoplastics
For consumers:
dosage, interactions, side effects
For professionals:
Prescribing Information
verteporfin Rate Add review
Rx C N X
Generic name:
verteporfin systemic
Brand name:
Visudyne
Drug class:
miscellaneous antineoplastics
For consumers:
dosage, interactions, side effects
For professionals:
AHFS DI Monograph
brolucizumab 7.0 3 reviews for brolucizumab to treat Macular Degeneration
Rx N
Generic name:
brolucizumab systemic
Brand name:
Beovu
Drug class:
anti-angiogenic ophthalmic agents
For consumers:
dosage, side effects
For professionals:
AHFS DI Monograph
Byooviz Rate Add review
Rx C N
Generic name:
ranibizumab ophthalmic
Drug class:
anti-angiogenic ophthalmic agents
For consumers:
dosage, interactions, side effects
For professionals:
Prescribing Information
Cimerli Rate Add review
Rx C N
Generic name:
ranibizumab ophthalmic
Drug class:
anti-angiogenic ophthalmic agents
For consumers:
dosage, interactions, side effects
For professionals:
Prescribing Information
Eylea HD 8.0 1 review for Eylea HD to treat Macular Degeneration
Rx C N
Generic name:
aflibercept ophthalmic
Drug class:
anti-angiogenic ophthalmic agents
For consumers:
dosage, side effects
For professionals:
Prescribing Information
Susvimo Rate Add review
Rx C N
Generic name:
ranibizumab ophthalmic
Drug class:
anti-angiogenic ophthalmic agents
For consumers:
dosage, interactions, side effects
For professionals:
Prescribing Information

Frequently asked questions

View more FAQ

Topics under Macular Degeneration

Learn more about Macular Degeneration

Care guides

Symptoms and treatments

Medicine.com guides (external)

Legend

Rating For ratings, users were asked how effective they found the medicine while considering positive/adverse effects and ease of use (1 = not effective, 10 = most effective).
Activity Activity is based on recent site visitor activity relative to other medications in the list.
Rx Prescription only.
OTC Over-the-counter.
Rx/OTC Prescription or Over-the-counter.
Off-label This medication may not be approved by the FDA for the treatment of this condition.
EUA An Emergency Use Authorization (EUA) allows the FDA to authorize unapproved medical products or unapproved uses of approved medical products to be used in a declared public health emergency when there are no adequate, approved, and available alternatives.
Expanded Access Expanded Access is a potential pathway for a patient with a serious or immediately life-threatening disease or condition to gain access to an investigational medical product (drug, biologic, or medical device) for treatment outside of clinical trials when no comparable or satisfactory alternative therapy options are available.
Pregnancy Category
A Adequate and well-controlled studies have failed to demonstrate a risk to the fetus in the first trimester of pregnancy (and there is no evidence of risk in later trimesters).
B Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women.
C Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use in pregnant women despite potential risks.
D There is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans, but potential benefits may warrant use in pregnant women despite potential risks.
X Studies in animals or humans have demonstrated fetal abnormalities and/or there is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience, and the risks involved in use in pregnant women clearly outweigh potential benefits.
N FDA has not classified the drug.
Controlled Substances Act (CSA) Schedule
M The drug has multiple schedules. The schedule may depend on the exact dosage form or strength of the medication.
U CSA Schedule is unknown.
N Is not subject to the Controlled Substances Act.
1 Has a high potential for abuse. Has no currently accepted medical use in treatment in the United States. There is a lack of accepted safety for use under medical supervision.
2 Has a high potential for abuse. Has a currently accepted medical use in treatment in the United States or a currently accepted medical use with severe restrictions. Abuse may lead to severe psychological or physical dependence.
3 Has a potential for abuse less than those in schedules 1 and 2. Has a currently accepted medical use in treatment in the United States. Abuse may lead to moderate or low physical dependence or high psychological dependence.
4 Has a low potential for abuse relative to those in schedule 3. It has a currently accepted medical use in treatment in the United States. Abuse may lead to limited physical dependence or psychological dependence relative to those in schedule 3.
5 Has a low potential for abuse relative to those in schedule 4. Has a currently accepted medical use in treatment in the United States. Abuse may lead to limited physical dependence or psychological dependence relative to those in schedule 4.
Alcohol
X Interacts with Alcohol.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.